R-EPOCH and cART

Phase 2Completed
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lymphoma, AIDS Related

Conditions

Lymphoma, AIDS Related, HIV Infections

Trial Timeline

Feb 1, 2008 → Sep 1, 2013

About R-EPOCH and cART

R-EPOCH and cART is a phase 2 stage product being developed by Roche for Lymphoma, AIDS Related. The current trial status is completed. This product is registered under clinical trial identifier NCT00799136. Target conditions include Lymphoma, AIDS Related, HIV Infections.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00799136Phase 2Completed

Competing Products

20 competing products in Lymphoma, AIDS Related

See all competitors
ProductCompanyStageHype Score
AFM13AffimedPhase 2
44
Pirtobrutinib + Brexucabtagene AutoleucelEli LillyPhase 2
52
EnzastaurinEli LillyPhase 2
52
Avastin + Gemcitabine + Oxaliplatin + Pegaspargase + DexamethasoneEli LillyPhase 2
52
Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)Eli LillyPhase 2
52
VIP152 + BTKiVincerx PharmaPhase 1
25
Tomivosertib (eFT-508)eFFECTOR TherapeuticsPhase 1/2
33
Nanatinostat in combination with valganciclovirViracta TherapeuticsPhase 2
44
Sepantronium BromideCothera BiosciencePhase 2
44
Copanlisib + RituximabCelltrionPhase 2
52
Rituximab + PembrolizumabCelltrionPhase 2
52
Rituximab + Methotrexate + Cytarabine InjectionCelltrionPhase 2
52
rituximabCelltrionPhase 1
33
CT-P10 + RituxanCelltrionPhase 3
77
Rituxan + CT-P10 + Cyclophosphamide + Vincristine + PrednisoneCelltrionPhase 3
77
Rituximab, lenalidomideCelltrionPhase 2
52
Rituximab + Lenalidomide + ValemetostatDaiichi SankyoPhase 1/2
41
Valemetostat tosylateDaiichi SankyoPhase 2
52
PLX3397Daiichi SankyoPhase 2
52
Valemetostat TosylateDaiichi SankyoPhase 2
52